{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:50:10Z","timestamp":1777589410526,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,8,20]],"date-time":"2010-08-20T00:00:00Z","timestamp":1282262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s11883-010-0134-3","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T04:44:53Z","timestamp":1282193093000},"page":"407-413","source":"Crossref","is-referenced-by-count":33,"title":["Coenzyme Q10 and Statin Myalgia: What is the Evidence?"],"prefix":"10.1007","volume":"12","author":[{"given":"Emilie","family":"Mas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor A.","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,20]]},"reference":[{"key":"134_CR1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjcard.2007.04.053","volume":"100","author":"SA Murphy","year":"2007","unstructured":"Murphy SA, Cannon CP, Wiviott SD, et al.: Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 2007, 100:1047\u20131051.","journal-title":"Am J Cardiol"},{"key":"134_CR2","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1001\/archinte.166.21.2307","volume":"166","author":"P Thavendiranathan","year":"2006","unstructured":"Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK: Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166:2307\u20132313.","journal-title":"Arch Intern Med"},{"key":"134_CR3","first-page":"640","volume":"16","author":"RY Mukhtar","year":"2005","unstructured":"Mukhtar RY, Reckless JP: Statin-induced myositis: a commonly encountered or rare side effect? Curr Opin Lipidol 2005, 16:640\u2013647.","journal-title":"Curr Opin Lipidol"},{"key":"134_CR4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11883-007-0050-3","volume":"9","author":"KA Sewright","year":"2007","unstructured":"Sewright KA, Clarkson PM, Thompson PD: Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007, 9:389\u2013396.","journal-title":"Curr Atheroscler Rep"},{"key":"134_CR5","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","volume":"33","author":"RC Pasternak","year":"2002","unstructured":"Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke 2002, 33:2337\u20132341.","journal-title":"Stroke"},{"key":"134_CR6","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","volume":"97","author":"PD Thompson","year":"2006","unstructured":"Thompson PD, Clarkson PM, Rosenson RS: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:69C\u201376C.","journal-title":"Am J Cardiol"},{"key":"134_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11883-009-0002-1","volume":"11","author":"SA Siddiqi","year":"2009","unstructured":"\u2022\u2022 Siddiqi SA, Thompson PD: How do you treat patients with myalgia who take statins? Curr Atheroscler Rep 2009, 11:9\u201314. This review provides recommendations regarding statin-related adverse events.","journal-title":"Curr Atheroscler Rep"},{"key":"134_CR8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, et al.: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403\u2013414.","journal-title":"Cardiovasc Drugs Ther"},{"key":"134_CR9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ecl.2008.11.002","volume":"38","author":"CV Venero","year":"2009","unstructured":"\u2022\u2022 Venero CV, Thompson PD: Managing statin myopathy. Endocrinol Metab Clin North Am 2009, 38:121\u2013136. This review examines symptoms of statin-induced myalgia and suggests clinical approaches to its management.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"134_CR10","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","volume":"97","author":"M Law","year":"2006","unstructured":"Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006, 97:52C\u201360C.","journal-title":"Am J Cardiol"},{"key":"134_CR11","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","volume":"114","author":"A Kashani","year":"2006","unstructured":"Kashani A, Phillips CO, Foody JM, et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788\u20132797.","journal-title":"Circulation"},{"key":"134_CR12","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563\u20131574.","journal-title":"N Engl J Med"},{"key":"134_CR13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0006-3002(57)90457-2","volume":"25","author":"FL Crane","year":"1957","unstructured":"Crane FL, Hatefi Y, Lester RL, Widmer C: Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta 1957, 25:220\u2013221.","journal-title":"Biochim Biophys Acta"},{"key":"134_CR14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/07315724.2001.10719063","volume":"20","author":"FL Crane","year":"2001","unstructured":"Crane FL: Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001, 20:591\u2013598.","journal-title":"J Am Coll Nutr"},{"key":"134_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbamem.2003.11.012","volume":"1660","author":"M Turunen","year":"2004","unstructured":"Turunen M, Olsson J, Dallner G: Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004, 1660:171\u2013199.","journal-title":"Biochim Biophys Acta"},{"key":"134_CR16","first-page":"536","volume":"24","author":"Y Tomono","year":"1986","unstructured":"Tomono Y, Hasegawa J, Seki T, et al.: Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int J Clin Pharmacol Ther Toxicol 1986, 24:536\u2013541.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"134_CR17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/biof.5520090218","volume":"9","author":"M Tomasetti","year":"1999","unstructured":"Tomasetti M, Alleva R, Solenghi MD, Littarru GP: Distribution of antioxidants among blood components and lipoproteins: significance of lipids\/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors 1999, 9:231\u2013240.","journal-title":"Biofactors"},{"key":"134_CR18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/13543781003727495","volume":"19","author":"JM Villalba","year":"2010","unstructured":"\u2022\u2022 Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ: Therapeutic use of coenzyme Q(10) and coenzyme Q(10)-related compounds and formulations. Expert Opin Investig Drugs 2010, 19:535\u2013554. This review addresses the therapeutic use of CoQ, including existing formulations and their effects on its bioavailability.","journal-title":"Expert Opin Investig Drugs"},{"key":"134_CR19","doi-asserted-by":"crossref","first-page":"8928","DOI":"10.1073\/pnas.87.22.8928","volume":"87","author":"RA Willis","year":"1990","unstructured":"Willis RA, Folkers K, Tucker JL, et al.: Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci U S A 1990, 87:8928\u20138930.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"134_CR20","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1073\/pnas.87.22.8931","volume":"87","author":"K Folkers","year":"1990","unstructured":"Folkers K, Langsjoen P, Willis R, et al.: Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990, 87:8931\u20138934.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"134_CR21","doi-asserted-by":"crossref","unstructured":"Ashton E, Windebank E, Skiba M, et al.: Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol 2010 (in press).","DOI":"10.1016\/j.ijcard.2009.12.028"},{"key":"134_CR22","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0002-9149(97)00174-4","volume":"79","author":"M Davidson","year":"1997","unstructured":"Davidson M, McKenney J, Stein E, et al.: Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997, 79:1475\u20131481.","journal-title":"Atorvastatin Study Group I. Am J Cardiol"},{"key":"134_CR23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","volume":"33","author":"G Ghirlanda","year":"1993","unstructured":"Ghirlanda G, Oradei A, Manto A, et al.: Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993, 33:226\u2013229.","journal-title":"J Clin Pharmacol"},{"key":"134_CR24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/jcp.46.11.1055","volume":"46","author":"GF Watts","year":"1993","unstructured":"Watts GF, Castelluccio C, Rice-Evans C, et al.: Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993, 46:1055\u20131057.","journal-title":"J Clin Pathol"},{"key":"134_CR25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0009-8981(97)06557-1","volume":"263","author":"JA Human","year":"1997","unstructured":"Human JA, Ubbink JB, Jerling JJ, et al.: The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 1997, 263:67\u201377.","journal-title":"Clin Chim Acta"},{"key":"134_CR26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0002-9149(97)89180-1","volume":"77","author":"R Laaksonen","year":"1996","unstructured":"Laaksonen R, Jokelainen K, Laakso J, et al.: The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996, 77:851\u2013854.","journal-title":"Am J Cardiol"},{"key":"134_CR27","first-page":"517","volume":"125","author":"R Laaksonen","year":"1995","unstructured":"Laaksonen R, Riihimaki A, Laitila J, et al.: Serum and muscle tissue ubiquinone levels in healthy subjects. J Lab Clin Med 1995, 125:517\u2013521.","journal-title":"J Lab Clin Med"},{"key":"134_CR28","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1016\/j.atherosclerosis.2007.06.010","volume":"195","author":"H Mabuchi","year":"2007","unstructured":"Mabuchi H, Nohara A, Kobayashi J, et al.: Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007, 195:e182\u2013189.","journal-title":"Atherosclerosis"},{"issue":"Suppl","key":"134_CR29","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.mito.2007.03.002","volume":"7","author":"GP Littarru","year":"2007","unstructured":"Littarru GP, Langsjoen P: Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007, 7(Suppl):S168\u2013174.","journal-title":"Mitochondrion"},{"key":"134_CR30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biof.5520180213","volume":"18","author":"S Passi","year":"2003","unstructured":"Passi S, Stancato A, Aleo E, et al.: Statins lower plasma and lymphocyte ubiquinol\/ubiquinone without affecting other antioxidants and PUFA. Biofactors 2003, 18:113\u2013124.","journal-title":"Biofactors"},{"key":"134_CR31","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1067\/mhj.2001.116762","volume":"142","author":"BE Bleske","year":"2001","unstructured":"Bleske BE, Willis RA, Anthony M, et al.: The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 2001, 142:E2.","journal-title":"Am Heart J"},{"key":"134_CR32","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","volume":"49","author":"L Marcoff","year":"2007","unstructured":"Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231\u20132237.","journal-title":"J Am Coll Cardiol"},{"key":"134_CR33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0005-2760(92)90081-6","volume":"1165","author":"P Low","year":"1992","unstructured":"Low P, Andersson M, Edlund C, Dallner G: Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. Biochim Biophys Acta 1992, 1165:102\u2013109.","journal-title":"Biochim Biophys Acta"},{"key":"134_CR34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF02576234","volume":"193","author":"M Fukami","year":"1993","unstructured":"Fukami M, Maeda N, Fukushige J, et al.: Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berl) 1993, 193:263\u2013273.","journal-title":"Res Exp Med (Berl)"},{"key":"134_CR35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.taap.2003.08.013","volume":"194","author":"WH Schaefer","year":"2004","unstructured":"Schaefer WH, Lawrence JW, Loughlin AF, et al.: Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004, 194:10\u201323.","journal-title":"Toxicol Appl Pharmacol"},{"key":"134_CR36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0009-9236(95)90266-X","volume":"57","author":"R Laaksonen","year":"1995","unstructured":"Laaksonen R, Jokelainen K, Sahi T, et al.: Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995, 57:62\u201366.","journal-title":"Clin Pharmacol Ther"},{"key":"134_CR37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","volume":"78","author":"H Paiva","year":"2005","unstructured":"Paiva H, Thelen KM, Van Coster R, et al.: High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005, 78:60\u201368.","journal-title":"Clin Pharmacol Ther"},{"key":"134_CR38","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.clpt.6100124","volume":"81","author":"BA Schick","year":"2007","unstructured":"Schick BA, Laaksonen R, Frohlich JJ, et al.: Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 2007, 81:650\u2013653.","journal-title":"Clin Pharmacol Ther"},{"key":"134_CR39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2007.12.010","volume":"8","author":"P Sirvent","year":"2008","unstructured":"Sirvent P, Mercier J, Lacampagne A: New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 2008, 8:333\u2013338.","journal-title":"Curr Opin Pharmacol"},{"key":"134_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18433\/J33018","volume":"11","author":"M Kobayashi","year":"2008","unstructured":"Kobayashi M, Kagawa T, Narumi K, et al.: Bicarbonate supplementation as a preventive way in statins-induced muscle damage. J Pharm Pharm Sci 2008, 11:1\u20138.","journal-title":"J Pharm Pharm Sci"},{"key":"134_CR41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","volume":"8","author":"BA Golomb","year":"2008","unstructured":"Golomb BA, Evans MA: Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008, 8:373\u2013418.","journal-title":"Am J Cardiovasc Drugs"},{"key":"134_CR42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.nmd.2009.10.014","volume":"20","author":"S Sacconi","year":"2010","unstructured":"Sacconi S, Trevisson E, Salviati L, et al.: Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord 2010, 20:44\u201348.","journal-title":"Neuromuscul Disord"},{"key":"134_CR43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1345\/aph.1G409","volume":"40","author":"HB Levy","year":"2006","unstructured":"Levy HB, Kohlhaas HK: Considerations for supplementing with coenzyme Q10 during statin therapy. Ann Pharmacother 2006, 40:290\u2013294.","journal-title":"Ann Pharmacother"},{"key":"134_CR44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.1996.04178.x","volume":"42","author":"G Pinieux De","year":"1996","unstructured":"De Pinieux G, Chariot P, Ammi-Said M, et al.: Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate\/pyruvate ratio. Br J Clin Pharmacol 1996, 42:333\u2013337.","journal-title":"Br J Clin Pharmacol"},{"key":"134_CR45","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","volume":"62","author":"C Lamperti","year":"2005","unstructured":"Lamperti C, Naini AB, Lucchini V, et al.: Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005, 62:1709\u20131712.","journal-title":"Arch Neurol"},{"key":"134_CR46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","volume":"6","author":"J Oh","year":"2007","unstructured":"Oh J, Ban MR, Miskie BA, et al.: Genetic determinants of statin intolerance. Lipids Health Dis 2007, 6:7.","journal-title":"Lipids Health Dis"},{"key":"134_CR47","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pone.0000097","volume":"1","author":"R Laaksonen","year":"2006","unstructured":"Laaksonen R, Katajamaa M, Paiva H, et al.: A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One 2006, 1:e97.","journal-title":"PLoS One"},{"key":"134_CR48","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","volume":"150","author":"TR Joy","year":"2009","unstructured":"\u2022\u2022 Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann Intern Med 2009, 150:858\u2013868. This is a review of statin-associated myopathy.","journal-title":"Ann Intern Med"},{"key":"134_CR49","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1097\/HJH.0b013e32832e1bd9","volume":"27","author":"TA Mori","year":"2009","unstructured":"Mori TA, Burke V, Puddey I, et al.: The effects of omega-3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens 2009, 27:1863\u20131872.","journal-title":"J Hypertens"},{"key":"134_CR50","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","volume":"99","author":"G Caso","year":"2007","unstructured":"Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409\u20131412.","journal-title":"Am J Cardiol"},{"key":"134_CR51","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","volume":"100","author":"JM Young","year":"2007","unstructured":"Young JM, Florkowski CM, Molyneux SL, et al.: Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007, 100:1400\u20131403.","journal-title":"Am J Cardiol"},{"key":"134_CR52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MOL.0b013e3283168ecd","volume":"19","author":"CF Schaars","year":"2008","unstructured":"\u2022\u2022 Schaars CF, Stalenhoef AF: Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008, 19:553\u2013557. This article reviews the effects of CoQ supplementation in statin-associated myopathy.","journal-title":"Curr Opin Lipidol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-010-0134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-010-0134-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-010-0134-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:58:33Z","timestamp":1559444313000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-010-0134-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,20]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["134"],"URL":"https:\/\/doi.org\/10.1007\/s11883-010-0134-3","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,20]]}}}